Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Expands By 8.0%

Cue Biopharma, Inc. (NASDAQ:CUE) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,080,000 shares, a growth of 8.0% from the November 30th total of 1,000,000 shares. Based on an average daily volume of 787,600 shares, the short-interest ratio is currently 1.4 days.

Cue Biopharma Trading Up 6.9 %

Shares of CUE opened at $1.09 on Thursday. The stock’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $1.01. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $69.05 million, a PE ratio of -1.21 and a beta of 1.66. Cue Biopharma has a 12-month low of $0.45 and a 12-month high of $3.20.

Insider Transactions at Cue Biopharma

In other news, CEO Daniel R. Passeri acquired 30,000 shares of Cue Biopharma stock in a transaction on Monday, December 16th. The shares were purchased at an average price of $1.03 per share, with a total value of $30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares in the company, valued at $169,515.34. This represents a 22.29 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Cue Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP grew its stake in shares of Cue Biopharma by 5.1% during the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock worth $221,000 after purchasing an additional 14,104 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Cue Biopharma during the 2nd quarter worth approximately $66,000. Good Life Advisors LLC grew its holdings in Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after purchasing an additional 75,000 shares during the period. Sigma Planning Corp grew its holdings in Cue Biopharma by 50.9% during the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after purchasing an additional 135,295 shares during the period. Finally, Geode Capital Management LLC increased its stake in Cue Biopharma by 3.3% in the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock valued at $385,000 after purchasing an additional 16,371 shares in the last quarter. 35.04% of the stock is owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.